Short Interest in NewAmsterdam Pharma (NASDAQ:NAMSW) Decreases By 30.0%

NewAmsterdam Pharma (NASDAQ:NAMSW) was the recipient of a large drop in short interest in November. As of November 15th, there was short interest totalling 3,500 shares, a drop of 30.0% from the October 31st total of 5,000 shares. Based on an average trading volume of 5,600 shares, the short-interest ratio is currently 0.6 days.

NewAmsterdam Pharma Trading Down 6.5 %

NAMSW stock traded down $0.63 during mid-day trading on Friday, reaching $9.06. The company’s stock had a trading volume of 1,116 shares, compared to its average volume of 10,056. NewAmsterdam Pharma has a 12 month low of $1.81 and a 12 month high of $16.75. The business’s 50 day moving average price is $9.33 and its 200 day moving average price is $8.59.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in NewAmsterdam Pharma stock. TFC Financial Management Inc. bought a new stake in NewAmsterdam Pharma (NASDAQ:NAMSW) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 10,000 shares of the company’s stock, valued at approximately $87,000.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.